NCNA

Announcements

Nothing here yet

Daily updates

• NuCana received a European composition-of-matter patent covering NUC-7738, strengthening intellectual property for its lead Phase 1/2 oncology asset being evaluated with pembrolizumab in PD-1-refractory metastatic melanoma.Sep 30, 2026

FDA designations

Nothing here yet

News

• NuCana announces grant of composition-of-matter patent for NUC-7738 in ChinaNov 5, 2025
• NuCana announces encouraging data for NUC-3373 in combination with anti-PD-1 therapyOct 14, 2025